De novo MET amplification in EGFR-mutant non-small cell lung cancer

被引：0
|
作者：
Lee, D. D. W. [1 ]
Wang, L. [2 ]
Lai, G. [2 ]
Lim, T. K. H. [2 ]
Tan, D. S. W. [2 ]
机构：
[1] Univ Malaya, Dept Clin Oncol, Fac Med, Kuala Lumpur, Malaysia
[2] Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
655P
引用
收藏
页码：S1649 / S1650
页数：3
相关论文
共 50 条
  • [1] Targeting MET amplification in EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Chaib, Imane
    Santarpia, Mariacarmela
    LANCET RESPIRATORY MEDICINE, 2020, 8 (11): : 1068 - 1070
  • [2] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    CANCERS, 2019, 11 (09)
  • [3] Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer
    Wang, K.
    Du, R.
    Roy, S.
    Vokes, N.
    Elamin, Y. Y.
    Hume, C. Bueno
    Skoulidis, F.
    Gay, C.
    Blumenschein, G.
    Fossella, F.
    Tsao, A.
    Lee, J. J.
    Rinsurongkawong, W.
    Rinsurongkawong, V.
    Gibbons, D.
    Vaporciyan, A.
    Zhang, J.
    Heymach, J.
    Altan, M.
    Le, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1016 - S1016
  • [4] Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer
    Syrigos, Konstantinos
    Kotteas, Ilias
    Paraskeva, Maria
    Gkiozos, Ioannis
    Boura, Paraskevi
    Tsagouli, Sofia
    Grapsa, Dimitra
    Charpidou, Andriani
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [5] Real World Outcomes in EGFR-Mutant Relapsed and De Novo Stage IV Non-Small Cell Lung Cancer (NSCLC)
    Gibson, A.
    Tudor, R.
    Dean, M.
    Elegbede, A.
    D'Silva, A.
    Hao, D.
    Bebb, D. G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S693 - S693
  • [6] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
    Naito, Yoichi
    Goto, Koichi
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040
  • [7] Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer
    Mi, J.
    Huang, Z.
    Zhang, R.
    Zeng, L.
    Xu, Q.
    Yang, H.
    Lizaso, A.
    Tong, F.
    Dong, X.
    Yang, N.
    Zhang, Y.
    ESMO OPEN, 2022, 7 (01)
  • [8] ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
    Desai, Aakash
    Vazquez, Tadana A.
    Arce, Keishla M.
    Corassa, Marcelo
    Mack, Philip C.
    Gray, Jhanelle E.
    Pellini, Bruna
    CANCERS, 2024, 16 (05)
  • [9] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [10] Patritumab Deruxtecan Is Efficacious in EGFR-Mutant Non-Small Cell Lung Cancer
    Zhang, H.
    Yu, X.
    Ye, J.
    Li, H.
    Hu, J.
    Tan, Y.
    CANCER DISCOVERY, 2023, 13 (12) : 2501 - 2501
12345